Q-omics provides the consensus-scored SCARF1 profile across patient tissues and cancer cell-line models. SCARF1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SCARF1 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, SCARF1 protein abundance shows 25,240 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where SCARF1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCARF1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCARF1 survival associations across molecular data types. SCARF1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (10) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCARF1 RNA expression–survival associations across cancer types. High SCARF1 expression shows unfavorable associations in UVM, LUSC and KIRP, but favorable associations in HNSC, KIRC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SCARF1 RNA expression.
This table summarizes SCARF1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SCARF1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCARF1 shows lower tumor expression in LUAD, LUSC, KIRP and UCEC and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher SCARF1 RNA expression in tumor versus normal tissue (log2 FC = +1.615, t-test p < 0.001).
This table shows molecular features associated with SCARF1 in patient tissues and cancer cell lines. In patient samples, SCARF1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SCARF1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
